Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer

ProMune Phase III lung cancer trial plans outlined in Coley's recent IPO prospectus filing. With licensee Pfizer funding ProMune for cancer applications, the bulk of the initial public offering proceeds will go toward expanding Coley's early-phase infectious disease program.